

REPOS THERAPEUTICS INC.
Form SC 13G/A
March 21, 2013

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

Repos Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

76028H209

(CUSIP Number)

March 15, 2013

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

S Rule 13d-1(b)
£ Rule 13d-1(c)
£ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1745 (12-02)

CUSIP No. 76028H209 13G/A Page 2 of 7 Pages

names of reporting persons

i.r.s. identification no. of above
persons (entities only)

1.

Perceptive Advisors LLC

2. check the appropriate box if a (a) £
group* (b) £
sec use only

3.

citizenship or place of organization

4. **Delaware, United States of America**

number of 5. sole voting power **0**
shares
beneficially 6. shared voting power **812,560**
owned by
each 7. sole dispositive power **0**
reporting
person 8. shared dispositive power **812,560**
with:

9. aggregate amount beneficially
owned by each reporting **812,560**
person

10. check box if the aggregate amount in
row (9) excludes certain shares (See
Instructions) £

11. percent of class represented **4.35%**
by amount in row (9)

12. type of reporting person (See **IA**
Instructions)

CUSIP No. 76028H209 13G/A Page 3 of 7 Pages

names of reporting persons

i.r.s. identification no. of above persons
(entities only)

13.

Joseph Edelman

14. check the appropriate box if a (a) £
group* (b) £
sec use only

15.

citizenship or place of organization

16. **United States of America**

number of shares beneficially owned by each reporting person with:	17. sole voting power	0
	18. shared voting power	812,560
	19. sole dispositive power	0
	20. shared dispositive power	812,560
21.	aggregate amount beneficially owned by each reporting person	812,560
22.	check box if the aggregate amount in row (9) excludes certain shares (See Instructions) £	
23.	percent of class represented by amount in row (9)	4.35%
24.	type of reporting person (See Instructions)	IN

CUSIP No. 76028H209 13G/A Page 4 of 7 Pages

Item 1.

(a) Name of Issuer: Repros Therapeutics, Inc.

(b) Address of Issuer's Principal Executive Offices: **2408 Timberloch Pl., Suite B-7 Woodlands, TX 77380**

Item 2.

(a) Name of Person Filing: **This Schedule 13G/A (the "Schedule") is being filed with respect to shares of Common Stock (as defined below) of Repros Therapeutics, Inc. (the "Issuer") which are beneficially owned by Perceptive Advisors LLC and Joseph Edelman (together, the "Reporting Persons"). See Item 4 below.**

(b) Address of Principal Business Office or, if none, Residence: **499 Park Avenue, 25th Floor New York, NY 10022**

(c) Citizenship: Perceptive Advisors LLC is a Delaware limited liability

company and Joseph Edelman is a United States Citizen.

(d) Title of Class of Securities: Common Stock

(e) CUSIP Number: 76028H209

If this statement is filed pursuant to Item 803 of Regulation S, 240.13d-1(b) or 240.13d-2(b) or 3. (c), check whether the person filing is a:

(a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) A church plan that is excluded from the definition of an

investment company under
section 3(c)(14) of the
Investment Company Act of
1940 (15 U.S.C. 80a-3);

(j)£ Group, in accordance with
§240.13d-1(b)(1)(ii)(J).

CUSIP No. 76028H209 13G/A Page 5 of 7 Pages

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned: The Reporting Persons beneficially own 812,560 shares of Common Stock held by a private investment fund to which Perceptive Advisors LLC serves as the investment manager. Mr. Edelman is the managing member of Perceptive Advisors LLC.
- (b) Percent of class: The beneficial ownership of 4.35% is based on the 18,643,986 outstanding shares of Common Stock of the Issuer as of March 8, 2013, as disclosed on the Issuer's 10-K

filed with the
SEC on March
18, 2013.

(c) Number of shares as to
which the person has:

Sole
power to
(i) vote or to 0
direct the
vote:

Shared
power to
(ii) vote or to 812,560
direct the
vote:

Sole
power to
(iii) dispose or to 0
direct the
disposition
of:

Shared
power to
(iv) dispose or to 812,560
direct the
disposition
of:

**Ownership of Five
Item 5 Percent or Less of a
Class**

If this statement is being filed
to report the fact that as of the
date hereof the reporting person
has ceased to be the beneficial
owner of more than five
percent of the class of
securities, check the following:
S.

Ownership of More
Item 6 than Five Percent on
Behalf of Another
Person

Not applicable.

Item 7. Identification and
Classification of the
Subsidiary which
Acquired the Security
Being Reported on by
the Parent Holding
Company or Control
Person.

Not applicable.

CUSIP No. 76028H209 13G/A Page 6 of 7 Pages

Identification
and
Item 8. Classification
of Members
of the Group.

Not applicable.

Notice of
Item 9. Dissolution of
Group.

Not applicable.

Item 10. Certification

The following
certification
shall be
included if the
statement is
filed pursuant
to
§240.13d-1(b):

(a) By signing
below I certify
that, to the best
of my
knowledge and
belief, the
securities
referred to
above were
acquired and
are held in the
ordinary course
of business and
were not
acquired and
are not held for
the purpose of
or with the
effect of
changing or

influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. S

CUSIP No. 76028H209 13G/A Page 7 of 7 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

March 20, 2013

Date

PERCEPTIVE ADVISORS LLC

/s/ Joseph Edelman

Signature

Joseph Edelman/Managing Member

Name/Title

March 20, 2013

Date

/s/ Joseph Edelman

Signature

Joseph Edelman

Name/Title

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)